Parkinson's Disease Dementia Clinical Trial
Official title:
A 76-week Prospective, Open-label, Multicenter Study to Evaluate the Long-term Effect of Rivastigmine Capsule and Transdermal Patch on Worsening of the Underlying Motor Symptoms of PD in Patients With Mild to Moderately Severe Dementia Associated With Parkinson's Disease (PDD)
The purpose of this study is to provide long-term safety data for rivastigmine capsule and transdermal patch treatments, in particular the effect of rivastigmine on worsening of the underlying motor symptoms of Parkinson's Disease (PD), in patients with mild to moderately severe dementia associated with PD.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02910102 -
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
|
Phase 2 | |
Terminated |
NCT02871427 -
Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder
|
Phase 2 | |
Active, not recruiting |
NCT02914366 -
Ambroxol as a Treatment for Parkinson's Disease Dementia
|
Phase 2 | |
Completed |
NCT02281474 -
Nilotinib in Cognitively Impaired Parkinson Disease Patients 001
|
Phase 1 | |
Completed |
NCT02708186 -
Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)
|
Phase 2 | |
Completed |
NCT00855686 -
Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies
|
Phase 4 | |
Recruiting |
NCT04844060 -
Cerebro Spinal Fluid Collection (CSF)
|
||
Recruiting |
NCT03413384 -
To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia
|
Phase 2 | |
Completed |
NCT02702102 -
Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies
|
Phase 2 | |
Completed |
NCT01102582 -
An Observational Study for the Prevalence of Neuropsychiatric Symptom in Parkinson's Disease Dementia
|
N/A |